Block Listing Return

Cambridge Cognition Holdings PLC
10 October 2024
 

10 October 2024

 

Cambridge Cognition Holdings plc

 

("Cambridge Cognition", the "Company" or the "Group")

 

Block Listing Return

 

The Company makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listings:

 

 

Name of applicant:

Cambridge Cognition Holdings plc

Name of scheme:

Share Options

Period of return:

From:

1 April 2024

To:

1 October 2024

Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission:

1,000,000 ordinary shares of £0.01 each in the Company admitted to trading on 23 March 2023

Balance of unallotted securities under scheme(s) from previous return:

466,316 ordinary shares

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

Nil

Less:  Number of securities issued/allotted under scheme(s) during period:

Nil

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

466,316 ordinary shares

 

Name of contact:

Simon McKeating

Telephone number of contact:

+44 (0)1223 810700

 

 

Enquiries:

 

Cambridge Cognition Holdings plc 

Dr Steven Powell, Chairman 

c/o Hudson Sandler 

 

Hudson Sandler (Financial PR and IR) 

Dan de Belder / Hattie Dreyfus 

 

Tel: 020 7796 4133 

cog@hudsonsandler.com

 

Panmure Liberum Limited (NOMAD and Joint Broker) 

Will Goode / Freddy Crossley / Mark Rogers

Rupert Dearden 

 

Tel: 020 7886 2968 

(Corporate Finance) 

(Corporate Broking) 

 

Dowgate Capital Limited (Joint Broker) 

David Poutney / Nick Chambers 

 

Tel: 020 3903 7715 

 


 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit:  https://cambridgecognition.com/ 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings